Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has experienced robust growth in its ACTH gel market, with expectations for continued expansion through 2025, bolstered by strong performance from key products such as Cortrophin Gel and Acthar Gel. Projections for adjusted operating margins suggest an increase from 25.4% in 2024 to 29.7% by 2028, alongside anticipated operating cash flow exceeding $630 million between 2025 and 2028. The company has also raised its FY 2025 revenue estimate to $269.5 million, reflecting increased demand and positive sales trends from both newly launched generics and established products, indicating a solid outlook for sustained growth.

Bears say

ANI Pharmaceuticals has experienced a notable decline in revenue within its Brands segment during the second and third quarters of 2024, attributed primarily to adverse market conditions affecting specific product molecules. The company has indicated that its Cortrophin revenue has consistently faced pricing pressure, with first-quarter results for both 2023 and 2024 falling short of expectations by approximately 10-12%, compounded by ongoing access issues linked to decreased funding for co-pay foundations serving Medicare patients. Additionally, while there were some positive adjustments in total revenue and EBITDA for the recent quarter, the market's outlook remains cautious due to significant anticipated revenue drops of over 30% in the first quarter of 2025 driven by both seasonality and external funding challenges.

ANI Pharma (ANIP) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 13 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.